Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2003
12/24/2003CA2488138A1 Treatment for depression and anxiety by the combination of a pde iv inhibitor and an antidepressant or an anxiolytic agent
12/24/2003CA2488117A1 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
12/24/2003CA2487948A1 Azole methylidene cyanide derivatives and their use as protein kinase modulators
12/24/2003CA2487122A1 Guanidine compounds as anesthetics and for treatment of nervous system disorders
12/23/2003US6667342 Benzenesulfonamide-derivatives and their use as medicaments
12/23/2003US6667336 Phenyl-thienyl-prop-1-en-3-yl-sarcosine derivatives; nontoxic; neurological and neuropsychiatric disorders; glycine transporter sequestering
12/23/2003US6667335 NMDA (N-methyl-D-aspartate)-receptor subtype selective blockers
12/23/2003US6667334 Imidazolidine derivatives, the production thereof, their use and pharmaceutical preparations containing the same
12/23/2003US6667331 Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
12/23/2003US6667327 Pyridine amido derivatives
12/23/2003US6667322 Useful for treatment of diseases such as obsessive compulsive disorder, panic attacks, anxiety, sexual dysfunction, eating disorders, obesity, addictive disorders
12/23/2003US6667320 For therapy of infalmmation; asthma, cancer, arthritis, multiple sclerosis; prophylaxis of infection of target cells by a human immunodeficiency virus (HIV)
12/23/2003US6667319 Neuropeptide Y Y5 receptor antagonists
12/23/2003US6667305 Alzheimer's disease; beta-amyloid peptide is a small fragment of the amyloid precursor protein
12/23/2003US6667304 Affinity for melatonin receptors; sleep disorders; N-(2-(2-methoxy-6H-pyrido(2',3':4,5)pyrrolo(2,1-a)isoindol-11 -yl)ethyl)acetamide; N-(2-(3-methoxy-6,7,8,9-tetrahydropyrido (3,2-b)indolizin-5-yl) ethyl)acetamide
12/23/2003US6667303 Aryl substituted 1,4-diazepanes and method of use thereof
12/23/2003US6667300 Purinyl substituted quinazoline-4-one derivatives
12/23/2003US6667297 Methods for treating neuropsychiatric disorders
12/23/2003US6667061 Microparticles comprising polymeric binder and injection vehicle, wherein microparticles are suspended in vehicle at concentration of greater than 30 mg/ml to form suspension having viscosity of 600 cp at 20 degrees C
12/23/2003US6667059 Odor-masking coating for a pharmaceutical preparation
12/23/2003US6667058 Oral forms of administration containing solid flupirtine with controlled release of active substance
12/23/2003CA2233178C (methylsulfonyl)phenyl-2-(5h)-furanones as cox-2 inhibitors
12/23/2003CA2223643C Sustained-release formulation of d-threo-methylphenidate
12/23/2003CA2149207C Compounds that inhibit t cell proliferation and methods using the same
12/18/2003WO2003104811A2 Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases
12/18/2003WO2003104807A1 Use of corticotroph-derived glycoprotein hormone to treat inflammation and potentiate glucocorticoid action
12/18/2003WO2003104441A2 Novel bacterial strain, compositions derived therefrom and methods of using same for treating beta-ap-associated deseases
12/18/2003WO2003104426A2 Isolated nucleic acid molecule encoding a novel centromere-associated motor protein, and uses thereof
12/18/2003WO2003104407A2 T cell receptor cdr3 sequences and methods for detection
12/18/2003WO2003104282A2 Immunoadhesin comprising a glycoprotein vi domain
12/18/2003WO2003104265A1 Compound having glycine transporter inhibition activity
12/18/2003WO2003104255A2 Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives
12/18/2003WO2003104253A2 9-alpha-substituted estratrienes as selectively active estrogen
12/18/2003WO2003104239A1 Compound for the treatment of cns disorders
12/18/2003WO2003104236A1 Calcitonin gene related peptide receptor antagonists
12/18/2003WO2003104235A1 Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]pyrazines and decahydropyrazino[1,2-a]azepines
12/18/2003WO2003104230A1 Bicyclic pyrimidine derivatives
12/18/2003WO2003104227A1 2-heteroaryl carboxamides
12/18/2003WO2003104226A1 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
12/18/2003WO2003104225A1 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
12/18/2003WO2003104223A1 Pyrazole-derivatives as p38 kinase inhibitors
12/18/2003WO2003104222A1 Bisindolyl-maleimid derivatives as kinase inhibitors
12/18/2003WO2003104219A1 Nf-kb inhibitors
12/18/2003WO2003104218A1 Nf-:b inhibitors
12/18/2003WO2003104208A1 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
12/18/2003WO2003104207A2 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
12/18/2003WO2003104205A1 Aryloximes
12/18/2003WO2003104204A1 Pyridazine derivatives
12/18/2003WO2003104203A1 Therapeutic molecules and methods-1
12/18/2003WO2003104195A1 4-(aryl or heteroaryl) -2-butylamine derivatives and their use as glucocorticoid ligans
12/18/2003WO2003104194A1 Method for preparing 1,3,5-triaminobenzene and hydrolyzing it into high-purity phloroglucinol
12/18/2003WO2003104193A1 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
12/18/2003WO2003104192A2 Controlled release formulation of lamotrigine
12/18/2003WO2003104178A1 Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif)
12/18/2003WO2003103772A1 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
12/18/2003WO2003103725A1 Compositions and methods for the diagnosis and treatment of tumor
12/18/2003WO2003103721A1 Gene therapeutic for cerebrovascular disorders
12/18/2003WO2003103698A1 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
12/18/2003WO2003103691A1 Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions
12/18/2003WO2003103687A1 Liquid formulation of decitabine and use of the same
12/18/2003WO2003103684A1 Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
12/18/2003WO2003103682A1 Compositions for cancer therapy saponins or sapogenins
12/18/2003WO2003103671A1 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
12/18/2003WO2003103670A1 Novel uses of dl-thp
12/18/2003WO2003103669A1 1-(4-piperidinyl) benzimidazolones as histamine h3 antagonists
12/18/2003WO2003103663A2 Substituted pyrrolines as kinase inhibitors
12/18/2003WO2003103662A2 Inhibitors of glycoprotein vi
12/18/2003WO2003103661A1 SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES
12/18/2003WO2003103660A1 Substituted phenylsulfonamide inhibitors of beta amyloid production
12/18/2003WO2003103652A1 METHODS OF TREATING ALZHEIMER'S DISEASE USING AROMATICALLY SUBSTITUTED omega-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES
12/18/2003WO2003103650A1 Active ingredient salts and esters of 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol and 3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methyl-propyl)-phenol
12/18/2003WO2003103643A1 Oral antidepressant formulation comprising a selective serotonin_reuptake inhibitor
12/18/2003WO2003103641A1 Patch
12/18/2003WO2003103640A1 Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
12/18/2003WO2003103635A1 Extended release formulation of divalproex sodium
12/18/2003WO2003103634A1 Sustained release oral dosage forms of gabapentin
12/18/2003WO2003103633A1 Nanoparticulate sterol formulations and sterol combinations
12/18/2003WO2003103632A1 Nanoparticulate polycosanol formulations and novel polycosanol combinations
12/18/2003WO2003103608A2 Neuroprotective synergy of erythropoietin and insulin-like growth factor
12/18/2003WO2003103604A2 Gamma lactams as prostaglandin agonists and use thereof
12/18/2003WO2003103603A2 Novel formate salt of o-desmethyl-venlafaxine
12/18/2003WO2003103584A2 Ether substituted imidazopyridines
12/18/2003WO2003103583A2 A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
12/18/2003WO2003097052A3 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
12/18/2003WO2003087087A3 Heterocyclic compounds and their use as modulators of p38 map kinase
12/18/2003WO2003082817A3 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
12/18/2003WO2003074558A3 Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, and treatments and animal models produced therefrom
12/18/2003WO2003074500A3 N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
12/18/2003WO2003068207A3 Partial dopamine-d2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity
12/18/2003WO2003066630A3 Quinolinone derivatives for treating cell proliferation related disorders
12/18/2003WO2003053431A3 Pharmaceutical compositions based on azetidine derivatives
12/18/2003WO2003053417A3 Method for making a tablet comprising a morphine type analgesic and resulting tablet
12/18/2003WO2003051917A3 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
12/18/2003WO2003050108A8 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
12/18/2003WO2003045362A3 Treatment of th1 dominated immunological disease states with non-endogenous gestagen compounds
12/18/2003WO2003044021A3 Substituted indolizine-like compounds and methods of use
12/18/2003WO2003042405A3 Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof
12/18/2003WO2003029437A3 Secreted proteins
12/18/2003WO2003027234A3 Small organic molecule regulators of cell proliferation
12/18/2003WO2003026558A3 Methods and apparatuses for assuring quality and safety of drug administration and medical products and kits
1 ... 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 ... 1833